216076-11-8

Basic information

• Product Name: 1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE
• Synonyms: 1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE;1-(2-chlorophenyl)-2-(4-pyridinyl)Ethanone
• CAS NO: 216076-11-8
• Molecular Formula: C₁₃H₁₀ClNO
• Molecular Weight: 231.68
• Mol File: 216076-11-8.mol

Chemical Properties

• Boiling Point: 357 °C at 760 mmHg
• Flash Point: 169.7 °C
• Appearance: /
• Density: 1.239 g/cm³
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: 1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE(216076-11-8)
• EPA Substance Registry System: 1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE(216076-11-8)

Safety Data

• Hazardous Substances Data: 216076-11-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE serves as a crucial building block in the synthesis of a variety of drugs and pharmaceutical products. Its unique structure allows it to be a key component in the development of new medications, contributing to the advancement of healthcare and treatment options.
Used in Organic Synthesis:
In the realm of organic synthesis, 1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE is utilized for the creation of complex organic molecules. Its versatile structure makes it a valuable intermediate in the synthesis of various organic compounds, expanding the scope of chemical research and development.
Used in Medicinal Chemistry:
1-(2-CHLORO-PHENYL)-2-PYRIDIN-4-YL-ETHANONE also holds potential in medicinal chemistry, where it can be employed in the design and synthesis of novel therapeutic agents. Its structural attributes make it a promising candidate for the development of drugs targeting specific biological pathways or receptors, thereby enhancing the efficacy of treatments for various diseases.

Upstream product

• 21384-45-2 1-(2-chlorobenzoyl)-2-methylaziridine 
• 108-89-4 picoline 
• 289686-74-4 2‐chloro‐N‐methoxy‐N‐methylbenzamide 
• 609-65-4 o-chlorobenzoyl chloride 

Downstream Products

• 1311460-00-0 C₁₄H₁₃ClN₂O 
• 224038-78-2 [4-(2-chlorophenyl)-5-(4-pyridyl)-1,3-thiazol-2-yl]amine 

Relevant articles and documents

SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF

The invention provides well-defined heterocyclic compounds that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype modulation of alpha 2 adrenergic receptors.

OXAZOLIDINE AND THIAZOLIDINE SELECTIVE SUBTYPE ALPHA 2 ADRENERGIC AGENTS AND METHODS FOR USE THEREOF

The invention provides oxazolidine and thiazolidine derivatives that are useful as subtype selective alpha 2 adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with selective subtype

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as selective adenosine A3 antagonists

To investigate the potency of an adenosine A3 receptor (A 3AR) antagonist as an anti-asthmatic drug, a novel series of 4-phenyl-5-pyridyl-1,3-thiazole derivatives was synthesized and evaluated in human adenosine A1, A

Synthesis and biological activities of 4-phenyl-5-pyridyl-1,3-thiazole derivatives as p38 MAP kinase inhibitors

A novel series of 4-phenyl-5-pyridyl-1,3-thiazole analogues possessing potent in vitro inhibitory activity against p38 mitogen-activated protein kinase and the release of tumor necrosis factor-α (TNF-α) from human monocytic THP-1 cells stimulated by lipopolysaccharide has been identified. Subsequent structure-activity relationship (SAR) studies and optimization for absorption, distribution, metabolism, and elimination (ADME) profiles led to the identification of compounds 7g and 10b as orally active lead candidates that block the in vivo production of proinflammatory cytokine (TNF-α). In pharmacokinetic studies, compound 10b showed good oral administration in mice and demonstrated significant in vivo anti-inflammatory activity in an anti-collagen monoclonal antibody-induced arthritis mouse model (minimum effective dose (MED)=30 mg/kg). Further elucidation of this class of compounds may provide novel anti-inflammatory agents, such as anti-rheumatoid arthritis drugs.

MEDICINAL COMPOSITIONS

The present invention relates to an agent for the prophylaxis or treatment of pain, an agent for suppressing activation of osteoclast, and an inhibitor of osteoclast formation, which contains a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor.

CONCOMITANT DRUGS

The present invention relates to a pharmaceutical agent containing one or more kinds of a p38 MAP kinase inhibitor and/or a TNF-α production inhibitor and one or more kinds of drugs selected from the group consisting of (1) a non-steroidal antiinflammator

Adenosine A3 receptor antagonists

A pharmaceutical composition for antagonizing adenosine at adenosine A3receptors which comprises a 1,3-azole compound substituted on the 4- or 5-position, or both, by a pyridyl which may be substituted is provided and can be used as a prophylactic and therapeutic agent for asthma, allergosis, inflammation, and so on.

p38MAP KINASE INHIBITORS

A 1,3-thiazole compound substituted at the 5-position by a pyridyl group optionally having substituent(s) has a superior p38 MAP kinase inhibitory activity and TNF-α production inhibitory activity.